# Traws Pharma, Inc. (TRAW) — delisting/forced [announced]
Source: SEC API (secapi.ai) · situation sit_e4ad0b43fcccd704fbf6 · retrieved 2026-08-11T15:49:19.373Z

## Overview
Traws Pharma, Inc. is a pharmaceutical company trading on the Nasdaq Capital Market under the ticker symbol TRAW.

On July 29, 2026, Traws Pharma, Inc. received a notification letter from Nasdaq stating that the Company's common stock closing bid price fell below $1.00 per share for at least 30 consecutive business days, placing it in non-compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement). The Company has 180 calendar days from July 29, 2026, until January 25, 2027, to regain compliance. If the closing bid price closes at or above $1.00 per share for a minimum of 10 consecutive business days (extendable to 20 days at Nasdaq's discretion) before January 25, 2027, Nasdaq will notify the Company that it has regained compliance and the matter will be resolved. If the Company fails to regain compliance by January 25, 2027, Nasdaq may grant a second 180-day grace period provided the Company meets other continued listing requirements and notifies Nasdaq of its intent to cure.

## Terms
- Counterparty: The Nasdaq Stock Market LLC · Price/share: $1

## Key dates
- Announced 2026-07-31 · Expiry 2027-01-25 · Expected close 2027-01-25

## Timeline
- 2026-07-31 · 8-K (0001104659-26-089220): 8-K - Traws Pharma, Inc. — *Traws Pharma, Inc. is a pharmaceutical company trading on the Nasdaq Capital Market under the ticker symbol TRAW.* On July 29, 2026, Traws Pharma, Inc. received a notification letter from Nasdaq stating that the Company's common stock closing bid price fell below $1.00 per share for at least 30 consecutive business days, placing it in non-compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement). The Company has 180 calendar days from July 29, 2026, until January 25, 2027, to regain compliance. If the closing bid price closes at or above $1.00 per share for a minimum of 10 consecutive business days (extendable to 20 days at Nasdaq's discretion) before January 25, 2027, Nasdaq will notify the Company that it has regained compliance and the matter will be resolved. If the Company fails to regain compliance by January 25, 2027, Nasdaq may grant a second 180-day grace period provided the Company meets other continued listing requirements and notifies Nasdaq of its intent to cure.
  https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-089220.txt

## Citations
- 0001104659-26-089220 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926089220